Ra Pharmaceuticals Inc Quick Ratio (RARX) starting from the fourth quarter 2019 to fourth quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ra Pharmaceuticals Inc   (RARX)

Ra Pharmaceuticals Inc 's Quick Ratio

RARX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2019, Quick Ratio fell to 14.26 below Ra Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Quick Ratio than Ra Pharmaceuticals Inc in fourth quarter 2019. While Quick Ratio total ranking in the fourth quarter 2019 has deteriorated compared to the prior quarter from 123 to 213.

Explain Quick Ratio?
How much Cash & cash equivalents RARX´s has?
What are RARX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RARX Quick Ratio (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4
Y / Y Current Liabilities Change 82.13 % 43.72 % 38.93 % 34.83 % 18.42 %
Y / Y Cash & cash equivalent Change 26.29 % 260.97 % 82.63 % 75.63 % 198.12 %
Quick Ratio MRQ 14.26 25.08 14.78 19.7 20.57
RARX's Total Ranking # 213 # 123 # 197 # 153 # 333
Seq. Current Liabilities Change 59.26 % -0.66 % 20.72 % -4.64 % 25.67 %
Seq. Cash & cash equivalent Change -9.44 % 68.55 % -9.42 % -8.66 % 158.85 %



Quick Ratio fourth quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 55
Healthcare Sector # 75
Overall Market # 213


Quick Ratio Statistics
High Average Low
25.08 15.41 8.17
(Sep 30 2019)   (Dec 31 2017)




Financial Statements
Ra Pharmaceuticals Inc 's Current Liabilities $ 19 Millions Visit RARX's Balance sheet
Ra Pharmaceuticals Inc 's Cash & cash equivalent $ 265 Millions Visit RARX's Balance sheet
Source of RARX's Sales Visit RARX's Sales by Geography


Cumulative Ra Pharmaceuticals Inc 's Quick Ratio

RARX's Quick Ratio for the trailling 12 Months

RARX Quick Ratio

 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months
Y / Y Current Liabilities TTM Growth 52.17 % 33.77 % 24.01 % 19.15 % 18.32 %
Y / Y Cash & cash equivalent TTM Growth 86.41 % 143.99 % 82.94 % 60.35 % 38.89 %
Quick Ratio TTM 17.84 20.02 16.49 15.82 14.57
Total Ranking TTM # 3528 # 3383 # 62 # 3680 # 69
Seq. Current Liabilities TTM Growth 19.33 % 8.92 % 9.02 % 7.39 % 4.9 %
Seq. Cash & cash equivalent TTM Growth 6.36 % 32.24 % 13.6 % 16.67 % 39.21 %

Quick ratio ranking by company, industry and sector >> Back to RARX Financial Strength Comparisons >> Go to Compare RARX Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q4 2019 to $18.58 millions, cumulative Quick Ratio decreased to 17.84 above the RARX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 447 other companies have achieved higher Quick Ratio than Ra Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2019 from 3383 to 3528.

Explain Quick Ratio?
How much Cash & cash equivalents RARX´s has?
What are RARX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 448
Healthcare Sector # 820
Within the Market # 3528


trailing twelve months Quick Ratio Statistics
High Average Low
20.02 13.06 4.52
(Sep 30 2019)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Dec 31 2019, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2019 MRQ Cash & cash equivalentDec 31 2019 MRQ Current Liabilities
Nextcure Inc   38.84 $ 334.605  Millions$ 8.614  Millions
Allakos Inc   37.97 $ 495.901  Millions$ 13.061  Millions
Tao Synergies Inc   36.28 $ 17.382  Millions$ 0.479  Millions
Adc Therapeutics Sa  34.71 $ 115.551  Millions$ 3.329  Millions
Principia Biopharma Inc   30.50 $ 315.580  Millions$ 10.348  Millions
Neurogene Inc   30.17 $ 143.093  Millions$ 4.743  Millions
Repare Therapeutics Inc   29.90 $ 94.797  Millions$ 3.170  Millions
Igc Pharma Inc   29.17 $ 25.610  Millions$ 0.878  Millions
Aptinyx Inc   28.40 $ 98.849  Millions$ 3.480  Millions
Aprea Therapeutics Inc   27.79 $ 65.676  Millions$ 2.364  Millions
Galectin Therapeutics Inc   27.49 $ 47.480  Millions$ 1.727  Millions
Guardion Health Sciences Inc   27.10 $ 11.116  Millions$ 0.410  Millions
Infinity Pharmaceuticals Inc   26.18 $ 42.444  Millions$ 1.621  Millions
Igm Biosciences Inc   25.31 $ 224.634  Millions$ 8.875  Millions
Aravive Inc   25.29 $ 65.134  Millions$ 2.575  Millions
Marker Therapeutics inc   24.55 $ 43.904  Millions$ 1.789  Millions
Milestone Pharmaceuticals Inc   24.31 $ 279.643  Millions$ 11.504  Millions
Aurinia Pharmaceuticals Inc   23.35 $ 612.038  Millions$ 26.215  Millions
Lftd Partners Inc   23.18 $ 4.385  Millions$ 0.189  Millions
Gossamer Bio Inc   22.75 $ 401.829  Millions$ 17.665  Millions
Provention Bio Inc   22.23 $ 85.373  Millions$ 3.840  Millions
Calithera Biosciences Inc   22.17 $ 157.361  Millions$ 7.097  Millions
Tff Pharmaceuticals Inc  21.85 $ 28.095  Millions$ 1.286  Millions
Atreca inc   21.72 $ 172.617  Millions$ 7.947  Millions
Cryoport inc   21.52 $ 94.733  Millions$ 4.402  Millions
Prothena Corporation Public Limited Company  21.21 $ 375.723  Millions$ 17.714  Millions
Q32 Bio Inc   21.20 $ 262.388  Millions$ 12.374  Millions
Arena Pharmaceuticals Inc   20.86 $ 739.565  Millions$ 35.453  Millions
Uniqure N v   20.83 $ 377.793  Millions$ 18.138  Millions
Pmv Pharmaceuticals Inc   20.03 $ 101.486  Millions$ 5.066  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.